In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmeceuticals

This article was originally published in The Rose Sheet

Executive Summary

The market for cosmeceuticals sold across mass, department, specialty and other retailers in the U.S. was estimated to be around $500 mil.-$600 mil. in 2005, according to Karen Young, president of marketing firm The Young Group. Exec presented during the Strategic Research Institute-sponsored Cosmeceuticals meeting in New York City June 8-9. In her presentation "Getting Your Brand Into the Channels That Count," Young noted the Internet remains an excellent means to attract new customers to a brand, and 80% of consumers regularly or occasionally purchase products online...

You may also be interested in...



Italy Opens Up On Trial Woes In A Pandemic

Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy. 

KKR Deal To Bolster JB Chemicals’ Expansion Efforts

US private equity firm KKR to acquire a majority stake in JB Chemicals, accelerating the Indian group's growth plans in branded formulations. Post a 54% stake acquisition for $414m via part-purchase from the founders and an open offer at INR 745/share, the PE's final stake could go up to 64.9% if founders offer more shares

Coronavirus Update: Moderna Hold Up, Sanofi and Regeneron's Kevzara Fails In Phase III

Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.

UsernamePublicRestriction

Register

SC070777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel